|Videos|April 28, 2023
Real-World Use of HER2-Directed Therapies in Colorectal Cancers
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
Dr Spira on the Data Supporting the Phase 3 Development of Iza-Bren in EGFR-Mutant NSCLC
5